BioMarin Buys Alesta for ALE1, First Oral Hypophosphatasia Therapy
BMRN sits 36% above its 52-week low of $49.259.
Summary
BioMarin is acquiring Alesta Therapeutics to gain ALE1, a potential first oral therapy for hypophosphatasia. The deal includes a $275 million upfront payment, plus additional payments upon achievement of development and regulatory milestones. Alesta will spin out all non-ALE1 assets to a new entity, and Alesta employees will transfer to the spinout entity prior to close; no Alesta employees will become BioMarin employees. The transaction is expected to have a modestly dilutive impact on 2026 financial results. The acquisition adds a clinical-stage program to BioMarin's pipeline, expanding its rare disease portfolio beyond Voxzogo and the Amicus deal, and follows strong Q2 results and raised guidance. No financial terms beyond the upfront were disclosed, but the deal is strategically significant for a company with a $12.9B market cap.
At the time of this announcement, BMRN was trading at $67.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.